Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
PURPOSE: Nonadherence to long-term treatments is often under-recognized by physicians and there is no gold standard for its assessment. In breast cancer, nonadherence to tamoxifen therapy after surgery constitutes a major obstacle to optimal outcomes. We sought to evaluate the rate of biochemical nonadherence to adjuvant tamoxifen using serum assessment and to examine its effects on short-term, distant disease-free survival (DDFS). PATIENTS AND METHODS: We studied 1,177 premenopausal women enrolled in a large prospective study (CANTO/NCT01993498). Definition of biochemical nonadherence was based on a tamoxifen serum level < 60 ng/mL, assessed 1 year after prescription. Self-reported nonadherence to tamoxifen therapy was collected at the same time through semistructured interviews. Survival analyses were conducted using an inverse probability weighted Cox proportional hazards model, using a propensity score based on age, staging, surgery, chemotherapy, and center size. RESULTS: Serum assessment of tamoxifen identified 16.0% of patients (n = 188) below the set adherence threshold. Patient-reported rate of nonadherence was lower (12.3%). Of 188 patients who did not adhere to the tamoxifen prescription, 55% self-reported adherence to tamoxifen. After a median follow-up of 24.2 months since tamoxifen serum assessment, patients who were biochemically nonadherent had significantly shorter DDFS (for distant recurrence or death, adjusted hazard ratio, 2.31; 95% CI, 1.05 to 5.06; P = .036), with 89.5% of patients alive without distant recurrence at 3 years in the nonadherent cohort versus 95.4% in the adherent cohort. CONCLUSION: Therapeutic drug monitoring may be a useful method to promptly identify patients who do not take adjuvant tamoxifen as prescribed and are at risk for poorer outcomes. Targeted interventions facilitating patient adherence are needed and have the potential to improve short-term breast cancer outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
McCambridge, J., Witton, J., & Elbourne, D. R. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.08.015 · Cited by 2,748 · cited 1×
“Nevertheless, in our study, the long-term observation, assessment of multiple clinical and biologic data, and evaluation of adherence using indirect and direct methods may minimize this effect.(37) Finally, our results may not be generalizable to other populations, because we restricted our analysis to the French prem…”
ResultSelf-management: Enabling and empowering patients living with cancer as a chronic illness
McCorkle, R., Ercolano, E., Lazenby, M., Schulman-Green, D., Schilling, L. S., Lorig, K., & Wagner, E. H. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20093 · Cited by 950 · cited 1×
“Fourth, we are aware that it is hard to isolate the true impact of nonadherence to tamoxifen on outcomes because it is part of a multitude of health-related behaviors influencing prognosis.(36) Indeed, because of the observational design, we cannot exclude unmeasured confounding affecting our survival analyses.”
BackgroundHershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676 · cited 1×
“However, pharmacy claims typically cannot be obtained in real time on an individual patient level and thus cannot be used to tailor treatment in the clinic.(1,10,11)”
BackgroundSelf-citationAustin, P. C. (2016) · Statistics in Medicine · doi:10.1002/sim.7084 · Cited by 542 · cited 1×
“Nevertheless, we used a PS weighting including relevant, known prognostic factors, aiming for a comprehensive adjustment in our analyses.(27,28) Fifth, we cannot exclude the impact of awareness of being observed on adherence (the Hawthorne effect).”
MethodGarber, M. C., Nau, D. P., Erickson, S. R., Aikens, J. E., & Lawrence, J. B. (2004) · Medical Care · doi:10.1097/01.mlr.0000129496.05898.02 · Cited by 519
Abrahams, H. J. G., Gielissen, M. F. M., Schmits, I. C., Verhagen, C. A. H. H. V. M., Rovers, M. M., & Knoop, H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw099 · Cited by 383
The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study
McCowan, C., Wang, S., Thompson, A. M., Makubate, B., & Petrie, D. J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.464 · Cited by 137
Cited by
Franzoi, M. A., Agostinetto, E., Perachino, M., Del Mastro, L., de Azambuja, E., Vaz-Luis, I., Partridge, A. H., & Lambertini, M. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30666-5 · Cited by 290
Self-citationVaz-Luis, I., Masiero, M., Cavaletti, G., Cervantes, A., Chlebowski, R. T., Curigliano, G., Felip, E., Ferreira, A. R., Ganz, P. A., Hegarty, J., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.1941 · Cited by 208
Self-citationDi Meglio, A., Havas, J., Gbenou, A. S., Martin, E., El-Mouhebb, M., Pistilli, B., Menvielle, G., Dumas, A., Everhard, S., Martin, A.-L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.00277 · Cited by 76
“Greater treatment-related symptom burden is among the main reasons for nonadherence and discontinuation of endocrine therapy that ultimately can contribute to poorer clinical outcomes.(81,82) In the context of recently consolidated strategies of endocrine therapy escalation,(83-85) particular attention should be given…”
BackgroundSelf-citationImplementing a PROACTive Care Pathway to Empower and Support Survivors of Breast Cancer
Franzoi, M. A., Degousée, L., Martin, E., Semedo, P. M., Aupomerol, M., Soldato, D., Di Meglio, A., Chiodi, C., Barbier, A., Chaouachi, H., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00016 · Cited by 18
Self-citation
Metadata
- Authors
- Pistilli, B., Paci, A., Ferreira, A. R., Di Meglio, A., Poinsignon, V., Bardet, A., Menvielle, G., Dumas, A., Pinto, S., Dauchy, S., Fasse, L., Cottu, P. H., Lerebours, F., Coutant, C., Lesur, A., Tredan, O., Soulie, P., Vanlemmens, L., Jouannaud, C., Levy, C., Everhard, S., Arveux, P., Martin, A. L., Dima, A., Lin, N. U., Partridge, A. H., Delaloge, S., Michiels, S., André, F., & Vaz-Luis, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-08-20
- Volume
- 38
- Issue
- 24
- Pages
- 2762-2772
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3036415919
- Cited by
- 147
- References
- 10
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.